SMOKING CESSATION AND RELAPSE PREVENTION
We published the first cost-effectiveness analysis of a motivational interviewing for smoking cessation and abstinence for low-income pregnant women, which was also the first published study to estimate clinical benefits in terms of life-years and quality-adjusted life-years when low-income pregnant women quit smoking and continue to abstain. We estimated cost savings to society for reaching this underserved and vulnerable population offering alternative approaches for policy makers.
economic evaluations of smoking cessation and relapse prevention
We are interested in assessing smoking cessation and relapse prevention programs among pregnant women and improve the quality of economic evaluations of such programs.
Our work in this area systematically reviewed and critically assessed economic evaluations of smoking cessation and relapse prevention programs among pregnant women.
Our research found that the return on investment in these programs will far outweigh the costs for this critical population. Prenatal smoking cessation and relapse prevention offers both health and economic benefits for women, infants, providers, and society.
IS MOTIVATIONAL INTERVIEWING A COST-EFFECTIVE INTERVENTION FOR SMOKING CESSATION AND RELAPSE PREVENTION?
Among low-income pregnant women, motivational interviewing can prevent relapse at relatively low cost, but it was more costly and no more effective than usual care in promoting smoking cessation.
HOW COST-EFFECTIVE ARE PHARMACO- AND BEHAVIORAL THERAPIES FOR SMOKING CESSATION?
Both pharmaco- and behavioral therapies for smoking cessation are cost-effective and even cost-saving in achieving public health and medical goals.